InvestorsHub Logo
Followers 45
Posts 428
Boards Moderated 0
Alias Born 03/04/2011

Re: Protector post# 107503

Saturday, 01/12/2013 12:11:00 PM

Saturday, January 12, 2013 12:11:00 PM

Post# of 346044
CP,

When Garnick made his comments "I know when to kill a drug" he was not referring to Avastin. He did not "jump ship" to leave
Genentech to join Peregrine.

If anything Avastin proves just how "ruthlessly effective" Dr. Garnick can be with a flawed drug that may have been the best possibility at that time.

PPHM is lucky to have such a tough street fighter on the team.

IMO It is important that you get your facts straight and stick to areas that you really know about so that your "credibility" remains high and you are not assumed to be just another "pumper" of a cheap biotech stock.

Your post 107513 is much better. IMO your math and understanding of dilution is still fuzzy (doesn't take into account additional dilution from low priced options for example) and recent forays into crystal ball gazing TA are open to attack and criticism.

However, IMO your summary of potential time line events going forward is really excellent. That is a really well thought out and "reasoned" bullish case. I hope you see the difference I am getting at and why. It is not necessary to "swing at every pitch in the dirt". In case you are not familiar with that American idiom, I am suggesting you pick your spots carefully.

I am surprised that you do not emphasize the "one salient fact" in all the recent BS about PPHM. That is ---- the 3mg unaffected arm of the 2nd line NSCLC trial was the best trial result in the history of that disease. That is the key fact. What the FDA will do or partners will do is open to speculation but that fact stands out.

Best Regards,
IMO (and meant with best intentions for strengthening PPHM comments)

RRdog
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News